PD-1/PD-L1免疫抑制剂治疗卵巢癌的临床应用进展

在女性生殖系统肿瘤中,卵巢癌的致死率是最高的。目前治疗卵巢癌的方法主要有手术联合放、化疗以及靶向治疗,但是对于患者的生存率没有明显改善。免疫治疗是近年提出的治疗卵巢恶性肿瘤的新策略,旨在增强患者免疫系统识别和攻击肿瘤细胞的能力。目前已有多种免疫疗法被证实有一定的疗效,其中程序性死亡蛋白-1（programmed death-1,PD-1）/程序性死亡蛋白配体-1（programmed death ligand-1,PD-L1）检查点抑制剂已进入临床用来改善晚期卵巢癌、复发性卵巢癌、铂敏感或者铂耐药卵巢癌患者的预后。最常见的PD-1/PD-L1免疫抑制剂包括纳武单抗、派姆单抗、阿特珠单抗、阿维单抗和度伐利尤单抗等,就这些免疫抑制剂在卵巢癌中的临床治疗进展,尤其是最新的联合治疗进展进行了综述。

Advances in the Treatment of Gynecological Malignancies during Pregnancy

Ovarian neoplasm has the highest mortality among female reproductive system tumors. The methods of treating ovarian cancer involve surgery combined with radiotherapy, chemotherapy and targeted therapy, yet there is no significant improvement in the survival rate of patients. Immunotherapy is a new strategy for malignant ovarian tumors and aims to boost the capacity of the immune system to recognize and attack tumor cells. Some of them have been proven to show effects, among which programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint inhibitors had been applied to improve the prognosis of advanced, recurrent platinum-sensitive or platinum-resistant ovarian cancer patients. PD-1/PD-L1 inhibitors include Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, etc. In this paper, we reviewed the progress of PD-1/PD-L1 inhibitors for ovarian cancer especially the combination therapy.